% | $
Quotes you view appear here for quick access.

Affymax, Inc. Message Board

  • karenyao07 karenyao07 Apr 11, 2013 1:45 AM Flag

    good news for those bought at $1-$2 but bad news for those bought at $20+

    Now the stock is less risk and less award.

    1. With Takeda taking full responsibility for OMONTYS, the drug will be back to market at very very chance (Note: a proved drug with 99.8% effective already). It is much less risk and the stock price should be $2-$3 before re-introducing and $5-$15 after re-introducing.

    2. Because Takeda receives a worldwide, exclusive royalty-bearing license under Affymax and joint Takeda-Affymax patents to develop, manufacture and commercialize OMONTYS, Affymax get less profit after re-introducing. The stock price won't reach $25-$80 range.

    3. Takeda may know the root-cause already but want to fully control OMONTYS and Affymax may ...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Dude, they sold the company's only product for $20 million plus royalties. How is this not a 50-cent stock?

    • Basically this 8-k puts a roof to this company... especially to this stock.
      Says: "worths no more than 180 Mil$".
      Actually until yesterday, there was no roof! That's the worst point.

      Then add up 50Mil$ cash..... but subtract AFFY admin costs until sales will get in Takeda.... subtract sueing costs from the 3 patients and from investors lawsuits.

      IMO, Mcap won't go over 100Mil$.
      The only way to create new value for this company is buying another drug and developing it.... but takes a decade and money.

      My personal compliments to the CEO who sold his soul for a new shining chair, I guess.
      A multi-bil$ drug...... sold for 180Mil$...... great manager action.

0.0930.0000(0.00%)Nov 27 12:32 PMEST